Cencora Reports Q4 & FY26 Results, Raises Dividend 10%, Outlines FY27 Outlook

Financial Results & Operational Overview

Cencora, Inc. (NYSE: COR) filed an 8-K disclosing its financial results for the fourth quarter and fiscal year ended September 30, 2026.

Q4 FY2026 Financial Highlights

• Revenue: $88.4 billion, up 5.5% year-over-year from the prior-year period.
• GAAP Diluted EPS: $2.71, compared to $(1.75) in Q4 FY2025.
• Adjusted Diluted EPS: $4.66, an increase of 21.4% year-over-year compared to $3.84 in Q4 FY2025.
• Adjusted Operating Income: $1.2 billion, up 22.1% year-over-year, driven by gross profit expansion from the OneOncology acquisition, offset partly by increased operating costs.

Full-Year FY2026 Financial Highlights

• Revenue: $337.4 billion, reflecting 5.0% annual growth.
• GAAP Diluted EPS: $17.95, up 125.5% year-over-year compared to $7.96 in FY2025.
• Adjusted Diluted EPS: $17.97, up 12.3% compared to $16.00 in FY2025.
• Adjusted Operating Income: $4.8 billion, representing a 14.0% increase.

Capital Allocation & Strategic Updates

• Dividend Hike: Approved a 10% increase in the quarterly dividend from $0.60 to $0.66 per common share, payable November 30, 2026, to shareholders of record as of November 13, 2026.
• M&A and Portfolio Optimization: Signed a definitive agreement to acquire American Oncology Network (350+ oncology providers across 21 states) and entered an agreement to divest its stake in Profarma (expected closing in Q1 FY2027).
• Segment Realignment: Effective Q1 FY2027, Cencora reorganized into two primary segments: Pharmaceutical Distribution and Services and Specialty Pharmaceutical and Provider Services, alongside Other.

Fiscal Year 2027 Guidance

• Adjusted Diluted EPS: Forecasted to be in the range of $19.40 to $19.75, representing expected growth of 8% to 10%.
• Revenue Growth: Expected overall revenue growth of 3% to 5%.